These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2010-018741-65 A PHASE 2, RANDOMIZED, DOUBLE-MASKED, CONTROLLED TRIAL TO ESTABLISH THE SAFETY AND EFFICACY OF INTRAVITREOUS INJECTIONS OF E10030 (ANTI-PDGF PEGYLATED APTAMER) GIVEN IN COMBINATION WITH LUCENTIS® IN S... 2012-01-17 due-trials
Reported results Terminated 2013-002997-33 A phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista™ (anti PDGF-b pegylated aptamer) administered in combination with... 2016-12-15 due-trials
Reported results 2013-003017-18 A phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of FovistaTM (anti PDGF-b pegylated aptamer) administered in combination wit... 2017-01-19 due-trials
Reported results 2013-003018-42 A phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista? (Anti PDGFB pegylated aptamer) administered in combination with e... 2017-10-11 due-trials
Reported results Terminated 2015-000518-23 A phase 2b randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista® (Anti-PDGFBB pegylated aptamer) administered in combination with... 2017-01-25 due-trials
Reported results Terminated 2015-000519-42 Role of multimodal imaging in the evaluation of anatomic alterations in neovascular Age-Related Macular Degeneration (AMD) subjects: 18 month Phase 2a open label study of Fovista® (anti-PDGF therapy) ... 2017-01-20 due-trials
Reported results 2015-003991-56 A Phase 2b Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura™ (Anti-C5 Aptamer) in Subjects with Geographic Atrophy Secondary to D... 2020-04-23 due-trials
Reported results 2017-003923-31 A Phase 2A Open-Label Trial to Assess the Safety of Zimura™ (Anti-C5) Administered in Combination With Lucentis® 0.5 mg in Treatment Naïve Subjects with Neovascular Age Related Macular Degeneration 2018-10-18 due-trials
Ongoing 2017-004783-35 A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease not-yet-due